441717-40-4Relevant articles and documents
A PROCESS FOR PREPARATION OF (2S, 5R)-7-OXO-6-SULPHOOXY-2-[((3R)-PYRROLIDINE-3-CARBONYL)-HYDRAZINO CARBONYL]-1,6-DIAZA-BICYCLO[3.2.1]OCTANE
-
Page/Page column 14, (2014/09/29)
A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2- [((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza- bicyclo[3.2.1]octane is disclosed comprising reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound
FUSED HETEROCYCLIC COMPOUND
-
Page/Page column 46, (2011/07/29)
The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.
Enzymatic resolution of n-substituted-β-prolines
Mendiola, Javier,Garcia-Cerrada, Susana,De Frutos, Oscar,De La Puente, Maria Luz,Gu, Rui Lin,Khau, Vien V.
scheme or table, p. 292 - 296 (2010/04/22)
A general and straightforward strategy for enzymatic resolution of N-substituted-β-proline has been successfully designed and developed in our research laboratories. A first affinity screen is followed by ratio enzyme/substrate optimization to source our
POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS
-
Page/Page column 188, (2008/06/13)
Disclosed are the ERK inhibitors of formula 1.0 and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
PYRROLIDINE DERIVATIVES AS ERK INHIBITORS
-
Page/Page column 196, (2010/11/28)
Disclosed are the ERK inhibitors of Formula (1.0): and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (1.0).